Canton Strategic Holdings, Inc. 8K

Canton Strategic Holdings, Inc. announced its first operating revenues from Canton Network activities, the sale of its legacy Gravitas biotech subsidiary, and governance and capital allocation actions as part of its Q2 2026 results.

On August 14, 2026, Canton Strategic Holdings, Inc. reported its financial and operational results for the quarter ended June 30, 2026, highlighting its first-ever operating revenues of approximately $1.5 million driven primarily by $1.3 million from a newly launched locking-as-a-service offering and $191,226 from Super Validator and validator operations on the Canton Network, alongside detailed disclosure of a net loss largely driven by unrealized losses on digital asset holdings, a significant increase in Canton Coin treasury and cash balances, the planned step-up in Super Validator weight through 2028, the sale of its legacy biotechnology subsidiary Gravitas Life Sciences, Inc. for a $3.5 million unsecured note plus contingent milestones, approval of a $50 million share repurchase program (with no repurchases to date), and the election of three new directors to strengthen governance.

Filing Facts

CIK

1861657

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-038508

Alert Tier

6